234 related articles for article (PubMed ID: 10620112)
1. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
Rünger TM; Emmert S; Schadendorf D; Diem C; Epe B; Hellfritsch D
J Invest Dermatol; 2000 Jan; 114(1):34-9. PubMed ID: 10620112
[TBL] [Abstract][Full Text] [Related]
2. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
3. Candidate genes for cross-resistance against DNA-damaging drugs.
Wittig R; Nessling M; Will RD; Mollenhauer J; Salowsky R; Münstermann E; Schick M; Helmbach H; Gschwendt B; Korn B; Kioschis P; Lichter P; Schadendorf D; Poustka A
Cancer Res; 2002 Nov; 62(22):6698-705. PubMed ID: 12438269
[TBL] [Abstract][Full Text] [Related]
4. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK; Schadendorf D; Röckmann H
Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency.
Helmbach H; Kern MA; Rossmann E; Renz K; Kissel C; Gschwendt B; Schadendorf D
J Invest Dermatol; 2002 Jun; 118(6):923-32. PubMed ID: 12060385
[TBL] [Abstract][Full Text] [Related]
6. Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines.
Nessling M; Kern MA; Schadendorf D; Lichter P
Cytogenet Cell Genet; 1999; 87(3-4):286-90. PubMed ID: 10702697
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
Christmann M; Pick M; Lage H; Schadendorf D; Kaina B
Int J Cancer; 2001 Apr; 92(1):123-9. PubMed ID: 11279615
[TBL] [Abstract][Full Text] [Related]
8. Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
Lage H; Christmann M; Kern MA; Dietel M; Pick M; Kaina B; Schadendorf D
Int J Cancer; 1999 Mar; 80(5):744-50. PubMed ID: 10048977
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
Passagne I; Evrard A; Winum JY; Depeille P; Cuq P; Montero JL; Cupissol D; Vian L
J Pharmacol Exp Ther; 2003 Nov; 307(2):816-23. PubMed ID: 12970393
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
Shellard SA; Hosking LK; Hill BT
Biochem Pharmacol; 1994 Mar; 47(5):775-9. PubMed ID: 8135853
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036.
Tapiero H; Yin MB; Catalin J; Paraire M; Deloffre P; Rustum Y; Bizzari JP; Tew KD
Anticancer Res; 1989; 9(6):1617-22. PubMed ID: 2627116
[TBL] [Abstract][Full Text] [Related]
13. Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine.
Vannini I; Bonafe M; Tesei A; Rosetti M; Fabbri F; Storci G; Ulivi P; Brigliadori G; Amadori D; Zoli W
Cell Oncol; 2007; 29(4):279-87. PubMed ID: 17641412
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
15. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
16. Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs.
Györffy B; Serra V; Materna V; Schäfer R; Dietel M; Schadendorf D; Lage H
Melanoma Res; 2006 Apr; 16(2):147-55. PubMed ID: 16567970
[TBL] [Abstract][Full Text] [Related]
17. Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells.
Mukai M; Kanzaki A; Chen ZS; Miyashita H; Sumizawa T; Furukawa T; Haraguchi M; Takebayashi Y; Takamatsu H; Akiyama S
Oncol Rep; 2002; 9(4):839-44. PubMed ID: 12066219
[TBL] [Abstract][Full Text] [Related]
18. Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines.
Lock RB; Hill BT
Int J Cancer; 1988 Sep; 42(3):373-81. PubMed ID: 3417366
[TBL] [Abstract][Full Text] [Related]
19. In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Fischel JL; Formento P; Etienne MC; Gioanni J; Frenay M; Deloffre P; Bizzari JP; Milano G
Cancer Chemother Pharmacol; 1990; 25(5):337-41. PubMed ID: 2306793
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of fotemustine as a potential agent for limb perfusion in melanoma.
Hayes MT; Bartley J; Parsons PG
Melanoma Res; 1998 Feb; 8(1):67-75. PubMed ID: 9508380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
